Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat in Rapidly Progressive ADPKD
NCT03523728Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Oct 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of venglustat in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Sanofi. Started Oct 2018; status: terminated.
02
Drugs
venglustat
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03523728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523728.